Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17900515 | 0.83 | GAA (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13903208 | 0.83 | GAA (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6258817 | 0.81 | IDO1 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL645073 | 0.80 | KDM4E (0.36) | SLC6A4SLC6A3 | |
| SCHEMBL1327227 | 0.79 | OPRM1 (0.41) | OPRD1SLC6A4SLC6A3 | |
| SCHEMBL643245 | 0.79 | IDO1 (0.38) | SLC6A4SLC6A3 | |
| SCHEMBL493016 | 0.79 | OPRL1 (0.42) | SLC6A4SLC6A3 | |
| SCHEMBL1326984 | 0.78 | KDM4E (0.40) | SLC6A4SLC6A3 | |
| SCHEMBL492709 | 0.77 | ALDH1A1 (0.34) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13476460 | 0.76 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119633-B2 | N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2150530-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-10-26 | — | — | EP | disclosed |
| EP-2150530-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008131947-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | OPRD1 8/4885SLC6A2 2372/4885SLC6A4 2704/4885 |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | SULT2A1, SULT1A1, SCN1A | OPRD1 61/4885SLC6A2 873/4885SLC6A4 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.